Skip to main content

BioMarker Strategies Gets $1.7M in Private Investment

NEW YORK (GenomeWeb News) – BioMarker Strategies has raised $1.7 million through a private funding round that included the Abell Foundation, the Baltimore-based company said today.

BioMarker Strategies is developing a tumor biopsy processing and testing system called SnapPath that is intended to quickly analyze a solid sample at the point of biopsy. It also is developing a series of pathway-based, ex-vivo biomarker tests to help physicians make therapeutic decisions for cancer patients.

The investment came in conjunction with the Maryland Biotechnology Investment Incentive Tax Credit Program. The firm is situated at the Johns Hopkins Science and Technology Park, located in East Baltimore.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.